AU2017213506B2 - Osteoclast inhibitors for pain - Google Patents
Osteoclast inhibitors for pain Download PDFInfo
- Publication number
- AU2017213506B2 AU2017213506B2 AU2017213506A AU2017213506A AU2017213506B2 AU 2017213506 B2 AU2017213506 B2 AU 2017213506B2 AU 2017213506 A AU2017213506 A AU 2017213506A AU 2017213506 A AU2017213506 A AU 2017213506A AU 2017213506 B2 AU2017213506 B2 AU 2017213506B2
- Authority
- AU
- Australia
- Prior art keywords
- zoledronic acid
- pain
- administered
- dosage form
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017213506A AU2017213506B2 (en) | 2014-05-27 | 2017-08-10 | Osteoclast inhibitors for pain |
AU2017272199A AU2017272199B2 (en) | 2014-05-27 | 2017-12-06 | Osteoclast inhibitors for pain |
AU2019204559A AU2019204559B2 (en) | 2014-05-27 | 2019-06-27 | Osteoclast inhibitors for pain |
Applications Claiming Priority (57)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201414228241A | 2014-05-27 | 2014-05-27 | |
US14/288,241 | 2014-05-27 | ||
US14/288,720 US8865757B1 (en) | 2014-05-28 | 2014-05-28 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US14/288,713 US8901162B1 (en) | 2014-01-30 | 2014-05-28 | Substituted imidazolium compounds for treating disease |
US14/288,716 US8835650B1 (en) | 2014-01-30 | 2014-05-28 | Substituted imidazolium compounds for treating disease |
US14/288,716 | 2014-05-28 | ||
US14/288,713 | 2014-05-28 | ||
US14/288,720 | 2014-05-28 | ||
US201462012112P | 2014-06-13 | 2014-06-13 | |
US62/012,112 | 2014-06-13 | ||
US14/310,811 | 2014-06-20 | ||
US14/310,811 US8822436B1 (en) | 2012-05-14 | 2014-06-20 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US14/336,642 | 2014-07-21 | ||
US14/336,642 US20140329773A1 (en) | 2012-05-14 | 2014-07-21 | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease |
US14/446,184 | 2014-07-29 | ||
US14/446,184 US9006279B1 (en) | 2014-01-30 | 2014-07-29 | Substituted imidazolium compounds for treating disease |
AUPCT/US2014/050427 | 2014-08-08 | ||
PCT/US2014/050427 WO2015060924A1 (fr) | 2013-10-25 | 2014-08-08 | Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies |
US14/457,659 | 2014-08-12 | ||
US14/457,659 US20140349974A1 (en) | 2014-08-12 | 2014-08-12 | Zoledronic acid dosage forms for the treatment of pain |
US14/481,097 | 2014-09-09 | ||
US14/481,097 US8962599B1 (en) | 2014-05-27 | 2014-09-09 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US201462053619P | 2014-09-22 | 2014-09-22 | |
US62/053,619 | 2014-09-22 | ||
US14/495,732 US9127069B1 (en) | 2014-06-11 | 2014-09-24 | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US14/495,732 | 2014-09-24 | ||
US14/530,556 US20150051175A1 (en) | 2012-05-14 | 2014-10-31 | Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain |
US14/530,556 | 2014-10-31 | ||
US14/536,526 US20150057250A1 (en) | 2012-05-14 | 2014-11-07 | Inhibitors of osteoclast activity for treating arthritis |
US14/536,526 | 2014-11-07 | ||
US14/538,709 | 2014-11-11 | ||
US14/538,709 US9290575B2 (en) | 2014-06-11 | 2014-11-11 | Compositions comprising RANK/RANKL antagonists and related compounds for treating pain |
US14/540,333 US9216168B1 (en) | 2014-05-27 | 2014-11-13 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US14/540,333 | 2014-11-13 | ||
US14/604,524 US9211257B2 (en) | 2012-05-14 | 2015-01-23 | Osteoclast inhibitors for knee conditions |
US14/604,524 | 2015-01-23 | ||
US14/605,822 | 2015-01-26 | ||
US14/605,822 US9216153B2 (en) | 2012-05-14 | 2015-01-26 | Osteoclast inhibitors for knee conditions |
US14/607,947 US9289384B2 (en) | 2012-05-14 | 2015-01-28 | Osteoclast inhibitors for knee conditions |
US14/607,985 US9289385B2 (en) | 2012-05-14 | 2015-01-28 | Osteoclast inhibitors for knee conditions |
US14/607,985 | 2015-01-28 | ||
US14/607,947 | 2015-01-28 | ||
US14/608,855 | 2015-01-29 | ||
US14/608,855 US9079927B1 (en) | 2014-05-27 | 2015-01-29 | Substituted imidazolium compounds for treating disease |
US14/625,457 | 2015-02-18 | ||
US14/625,457 US9427403B2 (en) | 2012-05-14 | 2015-02-18 | Methods for the safe administration of imidazole or imidazolium compounds |
US201562127214P | 2015-03-02 | 2015-03-02 | |
US62/127,214 | 2015-03-02 | ||
US14/635,857 US9283239B2 (en) | 2012-05-14 | 2015-03-02 | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US14/635,857 | 2015-03-02 | ||
US14/639,013 US9289441B2 (en) | 2014-08-08 | 2015-03-04 | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US14/639,013 | 2015-03-04 | ||
US14/686,551 | 2015-04-14 | ||
US14/686,551 US9408860B2 (en) | 2012-05-14 | 2015-04-14 | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
PCT/US2015/032739 WO2015184003A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'ostéoclastes contre la douleur |
AU2015267046A AU2015267046C1 (en) | 2014-05-27 | 2015-05-27 | Osteoclast inhibitors for pain |
AU2017213506A AU2017213506B2 (en) | 2014-05-27 | 2017-08-10 | Osteoclast inhibitors for pain |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015267046A Division AU2015267046C1 (en) | 2014-05-27 | 2015-05-27 | Osteoclast inhibitors for pain |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017272199A Division AU2017272199B2 (en) | 2014-05-27 | 2017-12-06 | Osteoclast inhibitors for pain |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2017213506A1 AU2017213506A1 (en) | 2017-08-31 |
AU2017213506B2 true AU2017213506B2 (en) | 2017-09-07 |
Family
ID=57483086
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017213506A Active AU2017213506B2 (en) | 2014-05-27 | 2017-08-10 | Osteoclast inhibitors for pain |
AU2017272199A Active AU2017272199B2 (en) | 2014-05-27 | 2017-12-06 | Osteoclast inhibitors for pain |
AU2019204559A Active AU2019204559B2 (en) | 2014-05-27 | 2019-06-27 | Osteoclast inhibitors for pain |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017272199A Active AU2017272199B2 (en) | 2014-05-27 | 2017-12-06 | Osteoclast inhibitors for pain |
AU2019204559A Active AU2019204559B2 (en) | 2014-05-27 | 2019-06-27 | Osteoclast inhibitors for pain |
Country Status (3)
Country | Link |
---|---|
AU (3) | AU2017213506B2 (fr) |
CA (3) | CA3194798A1 (fr) |
MY (1) | MY185481A (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013173330A1 (fr) * | 2012-05-14 | 2013-11-21 | Antecip Bioventures Ii Llc | Compositions comprenant de l'acide zolédronique ou des composés apparentés permettant de soulager une douleur inflammatoire et des états associés |
-
2015
- 2015-05-27 MY MYPI2016704377A patent/MY185481A/en unknown
- 2015-05-27 CA CA3194798A patent/CA3194798A1/fr active Pending
- 2015-05-27 CA CA3114271A patent/CA3114271C/fr active Active
- 2015-05-27 CA CA2950443A patent/CA2950443A1/fr not_active Abandoned
-
2017
- 2017-08-10 AU AU2017213506A patent/AU2017213506B2/en active Active
- 2017-12-06 AU AU2017272199A patent/AU2017272199B2/en active Active
-
2019
- 2019-06-27 AU AU2019204559A patent/AU2019204559B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013173330A1 (fr) * | 2012-05-14 | 2013-11-21 | Antecip Bioventures Ii Llc | Compositions comprenant de l'acide zolédronique ou des composés apparentés permettant de soulager une douleur inflammatoire et des états associés |
Also Published As
Publication number | Publication date |
---|---|
AU2017272199A1 (en) | 2017-12-21 |
AU2019204559B2 (en) | 2020-04-16 |
AU2019204559A1 (en) | 2019-07-18 |
MY185481A (en) | 2021-05-19 |
CA3114271A1 (fr) | 2015-12-03 |
CA3194798A1 (fr) | 2015-12-03 |
AU2017272199B2 (en) | 2019-03-28 |
CA2950443A1 (fr) | 2015-12-03 |
AU2017213506A1 (en) | 2017-08-31 |
CA3114271C (fr) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9694023B2 (en) | Methods for the safe administration of imidazole or imidazolium compounds | |
US9707245B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
US9895383B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9675626B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9700570B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9669040B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9795622B2 (en) | Neridronic acid for treating pain associated with a joint | |
US9662343B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9770457B2 (en) | Neridronic acid for treating bone marrow lesion | |
US9623036B2 (en) | Osteoclast inhibitors such as zoledronic acid for low back pain treatment | |
US20160331768A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain | |
US20170065622A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US20170056427A1 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
US20170071960A1 (en) | Osteoclast inhibitors for knee conditions | |
US20170049791A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US20170079995A1 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
US20170079996A1 (en) | Osteoclast Inhibitors for Knee Conditions | |
US20170065625A1 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
US9216153B2 (en) | Osteoclast inhibitors for knee conditions | |
WO2015184003A1 (fr) | Inhibiteurs d'ostéoclastes contre la douleur | |
AU2017213506B2 (en) | Osteoclast inhibitors for pain | |
AU2015267046B2 (en) | Osteoclast inhibitors for pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |